Main menu
Common skin conditions
NEWS
Join DermNet PRO
Read more
Quick links
Last Reviewed: October, 2026
Author: Dr Harriet Wilson, Dermatology Registrar, Waikato Hospital, New Zealand (2025).
Reviewing dermatologist: Dr Ian Coulson
Edited by the DermNet content department.
Introduction
Uses
Contraindications and precautions
PK/PD and Dosage
Benefits
Disadvantages
Side effects and risks
Moxidectin is an oral macrocyclic lactone anthelmintic drug used to treat onchocerciasis (river blindness), a disease caused by the filarial worm Onchocerca volvulus.
There are two major subgroups of macrocyclic lactones:
Moxidectin is approved by the US Food and Drug Administration (FDA) for the treatment of human onchocerciasis in adults and paediatric patients aged 4 years and older weighing at least 13 kg. It first received FDA approval for human use in 2018.
It is not approved for human use by the European Medicines Agency (Europe), Medicines and Healthcare products Regulatory Agency (United Kingdom), Therapeutic Goods Administration (Australia), or Medsafe (New Zealand).
It is being investigated for its potential therapeutic use in other human parasitic infestations, such as scabies. Efficacy has been demonstrated in eradicating sarcoptic mange in animals.
Contraindications
None are listed in the manufacturer’s label.
Warnings/precautions
Moxidectin, like ivermectin, does not effectively kill adult O. volvulus worms (macrofilariae). However, it interrupts the life cycle by targeting immature larvae (microfilariae).
The exact mechanism by which moxidectin exerts its microfilaricidal effects is not fully established. It is thought to work by binding to γ-aminobutyric acid (GABA) and glutamate-gated chloride channels in the nervous system of target parasites. This results in an influx of chloride ions, hyperpolarisation, flaccid paralysis, and eventual death. It is also assumed to have an embryostatic effect on O. volvulus, inhibiting microfilarial release from female worms.
Moxidectin is minimally metabolised in the body, primarily being excreted unchanged in the faeces. A negligible amount of the intact drug is eliminated renally. Dose adjustments are not required for mild or moderate renal impairment (≥30 mL/min).
Absorption is rapid, and it has a long half-life, with a mean terminal half-life of 23.3 days following a single 8 mg dose.
Moxidectin is available in 2 mg oral tablets.
The recommended dose for treating onchocerciasis in adult patients is 8 mg (four 2 mg tablets) as a single dose.
Recommended dose in paediatric patients:
It is taken as a single oral dose, with or without food.
Common adverse effects (> 10% of patients)
Mazzotti reaction
A common, major adverse effect of moxidectin is the Mazzotti reaction, an inflammatory response mounted by the host immune system due to rapid microfilarial death. It generally occurs and resolves in the first week .
Most patients with O. volvulus infection treated with moxidectin will have some form of Mazzotti reaction, and it is more common in those with a higher microfilarial load.
Manifestations include:
Encephalopathy due to Loa loa co-infection
While rare, microfilaricidal treatment of patients with loiasis (a filarial infection caused by Loa loa) and high levels of microfilaraemia can lead to serious complications such as encephalopathy, coma, and death.
Moxidectin has not been evaluated in patients concomitantly infected with L. loa and O. volvulus. Due to the risk for severe neurological complications, it is recommended that patients with exposure to L. loa-endemic regions undergo screening for loiasis before treatment with moxidectin.
Worsening of onchodermatitis
Patients with sowda, a severe localised form of onchocerciasis, may experience worsening of their cutaneous features (onchodermatitis) and limb oedema following treatment with moxidectin.
Approved datasheets are the official source of information for medicines, including approved uses, doses, and safety information. Check the individual datasheet in your country for information about medicines.
We suggest you refer to your national drug approval agency such as the Australian Therapeutic Goods Administration (TGA), US Food and Drug Administration (FDA), UK Medicines and Healthcare products regulatory agency (MHRA) / emc, and NZ Medsafe, or a national or state-approved formulary eg, the New Zealand Formulary (NZF) and New Zealand Formulary for Children (NZFC) and the British National Formulary (BNF) and British National Formulary for Children (BNFC).